AYJ Stock Overview
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 5/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Valneva SE Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €3.42 |
52 Week High | €7.79 |
52 Week Low | €2.99 |
Beta | 0.83 |
1 Month Change | -7.57% |
3 Month Change | -9.57% |
1 Year Change | -38.27% |
3 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -63.96% |
Recent News & Updates
Recent updates
Shareholder Returns
AYJ | DE Biotechs | DE Market | |
---|---|---|---|
7D | 0.9% | -1.5% | 1.9% |
1Y | -38.3% | -23.6% | 4.6% |
Return vs Industry: AYJ underperformed the German Biotechs industry which returned -21.9% over the past year.
Return vs Market: AYJ underperformed the German Market which returned 4.2% over the past year.
Price Volatility
AYJ volatility | |
---|---|
AYJ Average Weekly Movement | 8.0% |
Biotechs Industry Average Movement | 5.3% |
Market Average Movement | 5.0% |
10% most volatile stocks in DE Market | 10.4% |
10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: AYJ has not had significant price volatility in the past 3 months.
Volatility Over Time: AYJ's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1998 | 676 | Thomas Lingelbach | valneva.com |
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
Valneva SE Fundamentals Summary
AYJ fundamental statistics | |
---|---|
Market cap | €451.62m |
Earnings (TTM) | -€24.39m |
Revenue (TTM) | €152.96m |
3.0x
P/S Ratio-18.5x
P/E RatioIs AYJ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
AYJ income statement (TTM) | |
---|---|
Revenue | €152.96m |
Cost of Revenue | €162.45m |
Gross Profit | -€9.49m |
Other Expenses | €14.90m |
Earnings | -€24.39m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 13, 2024
Earnings per share (EPS) | -0.18 |
Gross Margin | -6.21% |
Net Profit Margin | -15.95% |
Debt/Equity Ratio | 95.9% |
How did AYJ perform over the long term?
See historical performance and comparison